Urinary Connective Tissue Growth Factor Level as an Early Non-Invasive Biomarker of Chronic Allograft Nephropathy = قياس عامل نمو النسيج الضام في البول كمؤشر مبكر لحدوث اعتلال الكلى المزروعة المزمن

2017 ◽  
Vol 46 (2) ◽  
pp. 331-344
Author(s):  
Emad Allam ◽  
Hussin Shaheen ◽  
Fawzy Hamed
Author(s):  
Riham Mahmoud Wagieh ◽  
Ahmed Hamdy Shabana ◽  
Hesham Mohammed Elserogy ◽  
Amr Mohamed Zoair

Objectives: Assessment of plasma level of connective tissue growth factor in congestive heart failure children, assessment of its diagnostic and prognostic role and correlate its level with clinical and echocardiographic assessment of congestive heart failure. Methods: Connective tissue growth factor level in the plasma was measured in 40 children; 20 of them have congestive heart failure, and 20 are healthy then, correlated with clinical parameters. Results: The diagnostic and prognostic value of it was evaluated. We compared its levels in both patients and healthy children. We found that connective tissue growth factor level was significantly increased in diseased children. Fractional shortening and ejection fraction correlated negatively with the plasma level of connective tissue growth factor. Heart rate, respiratory rate and calibrated integrated backscatter correlated positively with connective tissue growth factor. Connective tissue growth factor was significantly correlated with the class of heart failure according to Ross classification. Conclusions: Plasma connective tissue growth factor has a promising diagnostic and prognostic value as a biomarker for congestive heart failure in children with high sensitivity and specificity.


2011 ◽  
Vol 31 (4) ◽  
pp. 241-246 ◽  
Author(s):  
Olga Pivovarova ◽  
Eva Fisher ◽  
Katarzyna Dudziak ◽  
Iryna Ilkavets ◽  
Steven Dooley ◽  
...  

Chromosomal locus 6q23 is strongly linked to type 2 diabetes (T2DM) and related features including insulin secretion in various ethnic populations. Connective tissue growth factor (CTGF) gene is an interesting T2DM candidate gene in this chromosome region. CTGF is a key mediator of progressive pancreatic fibrosis up-regulated in type 2 diabetes. In contrast,CTGFinactivation in mice compromises islet cell proliferation during embryogenesis. The aim of our study was to investigate an impact ofCTGFgenetic variation on pancreatic beta-cell function and T2DM pathogenesis. We studied the effect of a commonCTGFpolymorphism rs9493150 on the risk of the T2DM development in three independent German cohorts. Specifically, the association betweenCTGFpolymorphism and non-invasive markers of beta-cell area derived from oral glucose tolerance test was studied in subjects without diabetes. Neither in the Metabolic Syndrome Berlin Potsdam (MESYBEPO) study (n= 1026) (OR = 0.637, CI (0.387–1.050);p= 0.077) nor in the European Prospective Investigation into Cancer and Nutrition-Potsdam (EPIC-Potsdam) (n= 3049) cohort (RR = 0.77 CI (0.49–1.20),p= 0.249 for the recessive homozygote in general model), a significant association with increased diabetes risk was observed. The risk allele of rs9493150 had also no effect on markers of beta-cell area in the combined analysis of the MESYBEPO and Tübingen Family Study (n= 1826). In conclusion, the polymorphism rs9493150 in the 5’-untranslated region of theCTGFgene has no association with T2DM risk and surrogate markers of beta-cell area.


2012 ◽  
Vol 179 (1-3) ◽  
pp. 10-14 ◽  
Author(s):  
Sabrina Bauer ◽  
Kristina Eisinger ◽  
Reiner Wiest ◽  
Thomas Karrasch ◽  
Marcus N. Scherer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document